prospectus is                     , 2017Table of ContentsTABLE OF CONTENTSPageProspectus Summary1The Offering10Summary Consolidated Financial Data12Risk Factors14Special Note Regarding Forward-Looking Statements15Industry And Market Data15Use of Proceeds16Capitalization17Dilution19Management20Executive Compensation28Certain Relationships And Related-Party Transactions37Principal Stockholders41Material U.S. Federal Income Tax Considerations forNon-U.S.Holders of Common Stock44Underwriting49Legal Matters56Experts56Where You Can Find Additional Information56Incorporation of Certain Information by Reference56Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in
emerging growth companies.9Table of ContentsThe OfferingCommon stock offered by us4,750,000 sharesCommon stock to be outstanding immediately after this offering26,481,259 sharesOption to purchase additional sharesWe have granted to the underwriters the option, exercisable for 30 days from the date of this prospectus, to purchase up to 712,500 additional shares of our common stock.Use of proceedsWe estimate that the net proceeds from the sale of our common stock sold in this offering will be approximately $69.4 million, assuming a public offering price of $15.66 per share, the last reported sale price of our common stock on The
assets and total stockholders’ equity by approximately $14.7 million, assuming the assumed public offering price remains the same and after deducting the estimated underwriting discounts and commissions.13Table of ContentsRISK FACTORSInvesting in our common stock involves a high degree of risk.
of $15.66 per share, the last reported sale price of our common stock on The NASDAQ Global Market on April 13, 2017, after deducting the estimated underwriting discounts and commissions and estimated offering expenses, will be approximately
and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates.Pending their use as described above, we intend to invest the net proceeds from this offering in marketable securities that may include
investment-grade interest-bearing securities, money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government.16Table of ContentsCAPITALIZATIONThe following table sets forth our cash, cash equivalents and short-term investments and total capitalization as of December 31, 2016 on:•an actual basis; and•an as adjusted basis to reflect the sale and issuance of 4,750,000 shares of our common stock in this offering, at an assumed public offering price of $15.66 per share, the last reported sale price of our common stock
increase the dilution to new investors by $(0.29) per share or $0.32 per share, respectively, assuming the assumed public offering price remains the same and after deducting the estimated underwriting discounts and commissions.If the underwriters exercise their option to purchase additional shares in full, our as adjusted net tangible book value per share after this
common stock reserved for future issuance under our 2016 Employee Stock Purchase Plan.19Table of ContentsMANAGEMENTThe following table provides information regarding our executive officers and directors as of December 31, 2016:NameAgePositionExecutive Officers:Matthew Patterson45President, Chief Executive Officer and DirectorNatalie Holles44Senior Vice President, Chief Operating OfficerThomas Soloway49Senior Vice President, Chief Financial OfficerSuyash Prasad, M.B.B.S., F.F.P.M.47Senior Vice President and Chief Medical OfficerMary Newman58Senior Vice President, Regulatory AffairsDavid Nagler64Senior Vice President, Human Resources and Corporate AffairsJohn Gray, Ph.D.53Senior Vice President, Research and DevelopmentNon-EmployeeDirectors:Jonathan Silverstein(1)49Chairman of Board of DirectorsLouis Lange, M.D., Ph.D.68DirectorScott Morrison(2)59DirectorKush Parmar, M.D., Ph.D.(1)(3)36DirectorThomas Schuetz, M.D., Ph.D.(2)56DirectorJulie Smith46DirectorStephen Squinto, Ph.D.(3)60DirectorThomas Woiwode, Ph.D.(2)(3)45Director(1)Member of the Nominating and Corporate Governance Committee(2)Member of the Audit Committee(3)Member of the Compensation CommitteeExecutive OfficersMatthew Pattersonis one of ourco-foundersand has served as our President and Chief
option to purchase 9,000 shares of common stock.27Table of ContentsEXECUTIVE COMPENSATIONThe following tables and accompanying narrative disclosure set forth information about the compensation provided to certain of our executive
In addition, the following shares of our common stock will be available for grant and issuance under the 2016 Plan:•shares subject to options or SARs granted under the 2016 Plan that cease to be subject to the option or SAR for any reason other than exercise of the option or SAR;•shares subject to awards granted under the 2016 Plan that are subsequently forfeited or repurchased by us at the original issue price;•shares subject to awards granted under the 2016 Plan that otherwise terminate without shares being issued;31Table of Contents•shares surrendered, cancelled, or exchanged for cash or a different award (or combination thereof);•shares subject to awards under the 2016 Plan that are used to pay the exercise price of an award or withheld to satisfy the tax withholding obligations related to any award;•shares reserved but not issued or subject to outstanding awards under the 2012 Plan on the date of this prospectus;•shares issuable upon the exercise of options or subject to other awards under the 2012 Plan prior to the date of this prospectus that cease to be subject to such options or other awards by forfeiture or otherwise after
Information reporting, but not backup withholding, will apply to a payment of proceeds, even if that payment is made outside of the United States, if you sell our common stock through anon-U.S.office of a broker that is:•a U.S. person (including a foreign branch or office of such person);•a “controlled foreign corporation” for U.S. federal income tax purposes;47Table of Contents•a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or•a foreign partnership if at any time during its tax year (i) one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or
not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.Any offer in Australia of the shares may only be made to persons, or Exempt Investors, who are “sophisticated investors” (within the
These transactions were exempt from the registration requirements of the Securities Act in reliance upon Rule 701 promulgated under the Securities Act.2.From March 15, 2014 to March 15, 2017, employees, directors, consultants and other service providers of the Registrant exercised options granted under the 2012 Plan aggregating 175,368 shares of common stock